Research
Molecular aspects of transformation; Oncogenes, tumor suppressor genes and transcription factors; Differentiation, cell-cycle and apoptosis; Antisense and gene therapy; Targeted drug delivery and pro-drug development; Bioinformatics and functional genomics. My laboratory is primarily interested in the molecular biological aspects of cancer. There is a strong genetic element associated with the development of cancer. While in the past cancer treatment was approached by use of drugs that would kill rapidly growing cells, recent advances in the molecular biology of cancer has opened up new avenues .Thus instead of phenomenological approaches, increasingly rational molecular targets are being explored for cancer control.Using cancers of breast, prostate, lung, pancreas and colon as model we use Bioinformatics approaches to target identification and validation to enable drug discovery for cancer treatment.
Education
1980 Ph.D Thesis - Factors influencing prostaglandin biosynthesis in ovine seminal vesicular membranes
Recent Publications
R. Narayanan, J.F. Klement, S.M. Rubin, K.A. Higgins & C.A. Rosen.
Identification of a naturally occurring transforming variant of the p65 subunit of NF-kB. Science: 256: 367-370,
1992.
R. Narayanan. Antisense therapy of cancer. In Vivo: 8: 787-794, 1994.
J.Y. Maltese,
H.W.Sharma & R. Narayanan. Sequence context of antisense Rel A/ NF-kB phosphorothioate determines
specificity. Nucleic. Acid Res. 7: 1146-1151, 1995.
H.W. Sharma, J.A. Sokaloski, J.R. Perez, A.C. Sartorelli & R. Narayanan. Differentiation of immortal cells inhibit telomerase activity. Proc. Natl. Acad. Sci. USA. 92: 12343-12346, 1996.
R. Narayanan. Harnessing the power of antisense for combination chemotherapy. J. of Natl. Cancer Inst. 89: 107-108, 1997.
S. Ramakrishnan, H.W. Sharma, A.D. Farris,K.M. Kaufman & R. Narayanan. Characterization of human telomerase complex. Proc. Natl. Acad. Sci. USA 94: 10075-10079, 1997.
S. Ramakrishnan, U. Eppenberger, H. Mueller, Y. Shinkai & R. Narayanan. Expression profile of the putative catalytic subunit of telomerase gene. Cancer Res. 58: 622-625, 1998. J. Elek, K.Park& R. Narayanan. Microarray based expression profiling in prostate tumors. In Vivo, 14: 173-182, 2000.
J. Elek, W. Pinzon, K. Park & R. Narayanan: Relevant genomics of neurotensin receptor in cancer. Anticancer Res. 20: 53-58, 2000.
D. Scheurle, M. Jahanzeb, R. S. Aronsohn, Laura Watzek, and R. Narayanan. HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved HercepTest, Anticancer Res. 20: 2091-2096, 2000.
D. Scheurle, M. P. DeYoung, D. M. Binninger, H. Page, M. Jahanzeb and R. Narayanan: Cancer gene discovery using digital differential display. Cancer Res. 60: 4037-4043, 2000.
DeYoung MP, Damania H, Scheurle D, Zylberberg C and Narayanan R: Bioinformatics based discovery of a novel factor with apparent specificity to colon cancer. In Vivo, 16:239-248,2002.
DeYoung MP, Scheurle D, Damania H, Zylberberg C and Narayanan R. Down's Syndrome-Associated Single Minded Gene As A Novel Tumor Marker Anticancer Research, 22: 3149-3158, 2002.
DeYoung MP, Tress M, and Narayanan R: Identification of Down’s Syndrome Critical Locus gene SIM2 as a novel drug therapy target for solid tumors. Proc. Natl. Acad. Sci. USA 100: 4760-4765, 2003.
DeYoung MP, Tress M, and Narayanan R: Down’s syndrome associated Single Minded gene 2 as a pancreatic cancer drug therapy target. Cancer Letters , 200, 25-31, 2003.
Mining genome databases for therapeutic gold: SIM2 is a novel target for treatment of solid tumors. Trends Pharmacol Sci. 2003 Oct;24 (10):508-10.
Mouse-to-Mouse Revelation: Genome Yields Cancer Drug Target. Genome News network, April, 2003.
Aleman MJ, DeYoung, MP, Tress, M, Keating, P, Perry, G and Narayanan, R. Inhibition of Single Minded 2 gene expression mediates tumor-selective apoptosis and differentiation in human colon cancer cells.
Proc Natl Acad Sci U S A. 2005 Sep 6; 102(36):12765-70. Epub 2005 Aug 29.
Kanezaki R, Toki T, Xu G, Narayanan, R., Ito E. Cloning and characterization of the novel chimeric gene p53/FXR2 in the acute megakaryoblastic leukemia cell line CMK11-5. Tohoku J Exp Med. 2006 July; 209:169-80.
Narayanan, R. Bioinformatics approaches to cancer gene discovery. Methods Mol Biol. 2007; 360: 13-31. Review.
Patents:
Methods of detecting a colon cancer cell- US patent approved, Jan 2004 (6,677,119)
Association of SIM2 with cancer- US patent approved, Aug 2004 (6,780,642).
Back to the top of this page
|